Celiac Disease and the Susceptibility of COVID-19 and the Risk of Severe COVID-19: A Mendelian Randomization Study

Jiuling Li, MS1, Aowen Tian, MS1, Dandan Yang, MS2, Miaoran Zhang, BS1, Lanlan Chen, BS3, Jianping Wen, PhD4,* and Peng Chen, PhD1,4,*

INTRODUCTION: Previous observational studies have found that the susceptibility of coronavirus disease 2019 (COVID-19) and the risk of severe COVID-19 are not increased in patients with celiac disease (CeD). However, the findings of observational studies are prone to bias due to reverse causation and confounding factors, especially in the case of a newly emerged disease. In this study, we aimed to further clarify the underlying relationship by both observational and Mendelian randomization (MR) analysis.

METHODS: This observational study was conducted in the UK Biobank cohort. Univariate and multivariate logistic regression analyses were performed to identify the risk factors of COVID-19 susceptibility and severe COVID-19. To understand the causality between CeD and COVID-19 susceptibility and severe COVID-19, we performed a 2-sample MR analysis.

RESULTS: Our observational study showed that patients with CeD had a lower susceptibility of COVID-19 (odds ratio [OR] = 0.699, P = 0.006) while CeD was not significantly associated with severe COVID-19 (P > 0.05). The findings from our MR study further demonstrated that both the susceptibility to COVID-19 (OR = 0.963, P = 0.006) and severe COVID-19 (OR = 0.919, P = 0.049) were lower in patients with CeD, although the former seemed to be specific to the UK Biobank cohort.

DISCUSSION: Our results suggested that it may be unnecessary to take extra COVID-19 precaution in patients with CeD.

SUPPLEMENTARY MATERIAL accompanies this paper at http://links.lww.com/CTG/A788

Clinical and Translational Gastroenterology 2022;13:e00480. https://doi.org/10.14309/ctg.0000000000000480

INTRODUCTION
Coronavirus disease 2019 (COVID-19), caused by the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread all over the world, leading to millions of confirmed cases and deaths (1). In a series of observational studies based on COVID-19 patient cohorts, severe COVID-19 was found to be associated with older age (2–4), male sex (2,4), and several comorbidities such as obesity (2,4,5) and diabetes (6,7).

Celiac disease (CeD) is a common autoimmune disease of the small intestine. The prevalence of CeD was estimated to be approximately 1.4% (8). The relationship between CeD and COVID-19 susceptibility has been broadly discussed (9–12). Several observational studies suggested that pediatric and adult patients with CeD are not at increased risk of COVID-19 susceptibility (9–11). Meanwhile, the severity of COVID-19 in patients with CeD had not significantly increased (12,13). The findings of observational studies are prone to bias due to reverse causation and confounding factors, especially in the case of a newly emerged disease.

Mendelian randomization (MR) analysis uses genetic variants to determine the causal effect of the risk factor on the outcome (14,15), which was considered to be advantageous to observational studies because it avoids the confounding factors and reverse causation. In this article, we report the results from an observational study based on the UK Biobank (UKB) cohort and a MR study that we believe will contribute to a further understanding on the susceptibility and severity of COVID-19 in patients with CeD. The results of our work would be informative.
to the clinical management of patients with CeD in the current and future COVID-19 pandemic.

**METHODS**

**Observational study**

The UK Biobank released COVID-19 test results and hospital inpatient data, as well as other phenotypes and genome-wide single-nucleotide polymorphism (SNP) genotypes. In our study, COVID-19 susceptibility was defined as a positive PCR test result of SARS-CoV-2 nucleotides. Severe COVID-19 was defined as COVID-19-related death (ICD-10 code: U071) and intensive care unit admission and ventilation machine use from 7 days before and up to 30 days after a patient’s first positive test for SARS-CoV-2. Confirmed SARS-CoV-2–negative individuals and SARS-CoV-2–positive patients without intensive care unit admission and ventilation machine use were used as control subjects for COVID-19 susceptibility and severity, respectively. CeD was defined based on ICD-10, ICD-9, and the question “Have you been diagnosed with celiac disease/gluten sensitivity?” The subjects with ICD-10 code K90.0 or ICD-9 code 5790 or those who were told by a doctor that they have CeD were grouped as patients with CeD. Diabetes was defined based on self-reported noncancer code 1223, ICD-10 codes (E110, E111, E112, E113, E114, E115, E116, E117, E118, and E119), ICD-9 codes (25000, 25009, 25010, 25019, 25029, 2503, 2504, 2505, and 25099), random glucose greater than 11.1 mmol/L, and glycated hemoglobin greater than 47.54 mmol/mol. In addition, if a participant was told by a doctor that he has diabetes, he was also defined as a patient with diabetes. Univariate logistic regression analysis was performed to identify the risk factors of COVID-19 susceptibility and severe COVID-19. Multivariate logistic regression models were adjusted for the significant risk factors ($P < 0.05$) identified in our univariate analyses to identify the independent risk factors of COVID-19 susceptibility and severe COVID-19.

**Mendelian randomization analysis**

We performed a 2-sample MR analysis to examine the causality between CeD and COVID-19 susceptibility and severe COVID-19, respectively. Instrumental variables (IVs) were proposed from CeD-associated SNPs in 2 published genome-wide association studies (GWASs; Table 1). Briefly, 36 independent SNPs (pairwise LD $r^2 < 0.05$) achieved genome-wide significance ($P < 5 \times 10^{-8}$) in 12,041 patients with CeD and 12,228 healthy controls of major European ancestry in a 2011 GWAS (16). Another 4 novel independent SNPs were identified after a sample expansion of 4,125 in 2020 (17). For the exposure (i.e., CeD), the association summary statistics of the IVs were drawn from the respective association studies.

For the proposed IVs, the association summary statistics with COVID-19 susceptibility or severe COVID-19 were obtained from the COVID-19 Host Genetics Initiative (COVID-19 HGI) GWAS (Table 1) (18). The susceptibility of COVID-19 was defined as ever had a positive laboratory test result, clinician diagnosis of COVID-19, or self-reported SARS-CoV-2 infection. Severe COVID-19 was defined by death, hospitalization, or respiratory support because of SARS-CoV-2 infection. Control samples were from individuals who were not confirmed cases. The proposed IVs with minor allele frequency $> 0.01$, imputation INFO score $> 0.6$, and heterogeneity $P$ value $> 0.05$ (Table 2) were used as the IVs in the MR analysis.

The MR analysis was conducted using an inverse-variance weighted model. The intercept of MR-Egger regression and the Cochran Q test were used to detect the pleiotropic effect and the heterogeneity of the IVs, respectively. Owing to the large sample size of the UK Biobank cohort (COVID-19 susceptibility: 6,490 cases [16.6%] and 328,577 controls [20.0%]; severe COVID-19: 309 cases [6%] and 328,577 controls [23.8%]), sensitivity MR analyses were conducted with the COVID-19 summary statistics calculated without the UKB samples.

**RESULTS**

**Sample characteristics of our observational study**

As summarized in Table 3, a total of 41,554 unrelated individuals of European ancestry with a SARS-CoV-2 test result were studied (8,267 SARS-CoV-2–positive vs 33,287 SARS-CoV-2–negative). Of these, 535 had a clinical diagnosis of CeD (74 SARS-CoV-2–positive).

**The observational relationship between CeD and COVID-19**

In our univariate regression analysis (Table 4 and Figure 1), body mass index (BMI) was associated with higher susceptibility of COVID-19 (odds ratio [OR] = 1.022, 95% CI: 1.017–1.027, $P < 0.001$) and severe COVID-19 (OR = 1.071, 95% CI: 1.055–1.087, $P < 0.001$). Male patients had a higher susceptibility of severe COVID-19 (OR = 2.075, 95% CI: 1.733–2.485, $P < 0.001$), but not significant for COVID-19 ($P = 0.132$). Intriguingly, age (OR = 0.942, 95% CI: 0.939–0.945, $P < 0.001$), diabetes (OR = 0.909, 95% CI: 0.841–0.984, $P = 0.018$), and gluten-free diet (OR = 0.365, 95% CI: 0.197–0.677, $P = 0.001$) decreased the susceptibility of COVID-19, while the first 2 were associated with higher risk of severe COVID-19 ($P < 0.001$).

In our multivariate regression analysis (Table 4 and Figure 1) adjusted for age, BMI, gluten-free diet, and diabetes, COVID-19

| Trait | First author/consortium | Year | Patients, N | Controls, N |
|-------|--------------------------|------|-------------|-------------|
| CeD   | Gosia Trynka             | 2011 | 12,041      | 12,228      |
| CeD   | Isis Ricaño-Ponce        | 2020 | 13,177      | 15,217      |
| COVID-19 susceptibility | COVID-19 HGI | 2021 | 38,984      | 1,644,784   |
| COVID-19 severity   | COVID-19 HGI        | 2021 | 5,101       | 1,383,241   |
| COVID-19 susceptibilitya | COVID-19 HGI | 2021 | 32,494      | 1,316,207   |
| COVID-19 severitya  | COVID-19 HGI        | 2021 | 4,792       | 1,054,664   |

COVID-19, coronavirus disease 2019; UKB, UK Biobank.

*aThe UKB samples were excluded in the sensitivity analysis.*
Table 2. The association of instrumental variables with celiac disease and COVID-19

| SNP        | EA/AA | Celiac disease |  | COVID-19 susceptibility |  | Severe COVID-19 |  | COVID-19 susceptibility^a |  | Severe COVID-19^a |
|------------|-------|----------------|---|-------------------------|---|----------------|---|--------------------------|---|----------------------|
|            |       | Beta (SE)      |  | P                       |   | Beta (SE)      |  | P                       |   | Beta (SE)             |
| rs1018326  | C/T   | 0.15 (0.02)    |   | 3.06E-16                |   | −0.01 (0.01)   |   | 0.33                     |   | −0.04 (0.03)   |
| rs1050976  | T/C   | −0.11 (0.02)   |   | 1.84E-09                |   | 0.01 (0.01)    |   | 0.28                     |   | −0.02 (0.03)   |
| rs1080746  | T/C   | −0.11 (0.02)   |   | 2.57E-08                |   | 0.00 (0.01)    |   | 0.65                     |   | 0.01 (0.03)   |
| rs10892258 | A/G   | −0.15 (0.02)   |   | 1.73E-11                |   | 0.02 (0.01)    |   | 0.12                     |   | 0.00 (0.01)   |
| rs11851414 | C/T   | 0.12 (0.02)    |   | 4.71E-08                |   | −0.03 (0.01)   |   | 0.02                     |   | −0.02 (0.03)   |
| rs11875687 | C/T   | 0.16 (0.03)    |   | 1.92E-10                |   | −0.02 (0.01)   |   | 0.09                     |   | −0.02 (0.04)   |
| rs12068671 | C/T   | −0.16 (0.02)   |   | 1.40E-10                |   | 0.00 (0.01)    |   | 0.73                     |   | 0.00 (0.03)   |
| rs13003464 | G/A   | 0.15 (0.02)    |   | 4.34E-16                |   | −0.02 (0.01)   |   | 0.10                     |   | −0.03 (0.03)   |
| rs1312308  | G/A   | −0.35 (0.03)   |   | 1.88E-38                |   | 0.01 (0.01)    |   | 0.28                     |   | 0.02 (0.04)   |
| rs1353248  | T/C   | −0.17 (0.02)   |   | 9.80E-09                |   | 0.00 (0.01)    |   | 0.79                     |   | −0.04 (0.04)   |
| rs182429   | A/G   | 0.15 (0.02)    |   | 8.49E-16                |   | 0.00 (0.01)    |   | 0.95                     |   | 0.01 (0.03)   |
| rs2030519  | G/A   | −0.28 (0.02)   |   | 3.00E-49                |   | 0.00 (0.01)    |   | 0.76                     |   | 0.06 (0.04)   |
| rs4445406  | C/T   | −0.14 (0.02)   |   | 5.42E-12                |   | 0.00 (0.01)    |   | 0.79                     |   | −0.01 (0.03)   |
| rs4821124  | C/T   | 0.15 (0.02)    |   | 5.72E-11                |   | −0.01 (0.01)   |   | 0.62                     |   | NA                   |
| rs55743914 | T/C   | 0.19 (0.02)    |   | 1.15E-18                |   | −0.01 (0.01)   |   | 0.46                     |   | 0.00 (0.04)   |
| rs61579022 | A/G   | 0.11 (0.02)    |   | 9.92E-09                |   | −0.01 (0.01)   |   | 0.56                     |   | −0.05 (0.03)   |
| rs61907765 | T/C   | 0.16 (0.02)    |   | 3.43E-13                |   | 0.02 (0.01)    |   | 0.15                     |   | 0.04 (0.03)   |
| rs6715106  | G/A   | −0.24 (0.04)   |   | 8.38E-09                |   | 0.01 (0.02)    |   | 0.53                     |   | 0.05 (0.06)   |
| rs6806528  | T/C   | 0.17 (0.03)    |   | 9.10E-09                |   | −0.03 (0.02)   |   | 0.07                     |   | −0.10 (0.05)   |
| rs7616215  | C/T   | 0.11 (0.02)    |   | 8.60E-09                |   | −0.01 (0.01)   |   | 0.15                     |   | 0.01 (0.03)   |
| rs79758729 | G/A   | 0.16 (0.03)    |   | 2.12E-08                |   | 0.02 (0.02)    |   | 0.18                     |   | 0.01 (0.04)   |
| rs9610686  | C/T   | 0.10 (0.02)    |   | 3.28E-08                |   | 0.00 (0.01)    |   | 0.71                     |   | −0.02 (0.03)   |
| rs990171   | A/C   | 0.18 (0.02)    |   | 1.23E-16                |   | 0.00 (0.01)    |   | 0.95                     |   | 0.01 (0.03)   |

The SNPs in COVID-19 GWAS with the heterogeneity P value less than 0.05 were excluded in this study.
AA, alternative allele; COVID-19, coronavirus disease 2019; EA, effect allele; GWAS, genome-wide association study; NA, not available; SNP, single-nucleotide polymorphism; UKB, UK Biobank.
^aThe UKB samples were excluded in the sensitivity analysis.
susceptibility in patients with CeD was lower than in the control subjects (OR = 0.699, 95% CI: 0.542–0.901, \( P = 0.006 \)). With the adjustment of age, sex, BMI, and diabetes, the risk of severe COVID-19 in patients with CeD was not significantly different from that in the control subjects (OR = 0.873, 95% CI: 0.256–2.975, \( P = 0.431 \)).

The causal relationship between CeD and COVID-19
Among the total 40 SNPs associated with CeD, 23 and 21 SNPs were used as IVs in the MR analysis to examine their causal association between CeD and COVID-19 susceptibility or severe COVID-19, respectively. None of the IVs were associated with COVID-19 at the Bonferroni corrected significance level (\( P < 0.002 \)) (Table 2). As shown in Figure 2 (Table 5), we found that CeD was causally associated with a significantly lower risk of both COVID-19 susceptibility (OR = 0.963, \( P = 0.006 \)) and severe COVID-19 (OR = 0.919, \( P = 0.049 \)). The former association became insignificant (\( P = 0.126 \)) in the sensitivity MR analysis, suggesting that the decreased susceptibility of COVID-19 could be primarily driven by the UKB cohort. However, the decreased risk of severe COVID-19 in patients with CeD was not dominated by the UKB sample (\( P = 0.037 \)). We did not observe significant heterogeneity or pleiotropic effects of the IVs in these analyses. The forest plot of the causal effects of CeD-associated IVs on COVID-19 is presented in the Supplementary Figure (see Supplementary Digital Content 1, http://links.lww.com/CTG/A788).

DISCUSSION
Observational studies concluded that there is no difference in COVID-19 susceptibility or severe COVID-19 between patients with CeD and control individuals. In this work, our observational study in the UKB cohort showed that COVID-19 susceptibility was lower in patients with CeD, while the risk of severe COVID-19 was not significant. The association between CeD and COVID-19 susceptibility was further supported by the causal association inferred by using genetic instrumental variables. Notably, we also showed that the risk of severe COVID-19 was causally lower in patients with CeD in our MR analysis.

The potential mechanism underlying the lower risk of severe COVID-19 in patients with CeD is unclear. Patients with CeD may have a higher standard of behavior hygiene as compared with other individuals, which may lead to a lower virus load. On the other hand, we speculate that CeD-associated genetic variations that

---

**Table 3. Sample characteristics of our observational study**

| Sample characteristics | COVID-19 susceptibility | Severe COVID-19 |
|------------------------|-------------------------|-----------------|
|                        | Negative (n = 33,327)    | Positive (n = 8,267) | Nonsevere (n = 7,711) | Severe (n = 556) |
| Age (yr) [\( \pm SD \)] | 70.37 [7.80]             | 66.34 [8.64]       | 65.80 [8.51]            | 73.87 [6.65]      |
| Male (%)                | 15,915 (47.81)           | 4,029 (48.74)      | 3,666 (47.54)           | 363 (65.29)       |
| BMI (kg/m²) [\( \pm SD \)] | 27.71 [4.89]            | 28.25 [5.04]       | 28.11 [4.96]            | 30.13 [5.65]      |
| Diabetes (%)            | 3,760 (11.30)            | 858 (10.38)        | 718 (9.31)              | 140 (25.18)       |
| Gluten-free diet (%)    | 121 (0.36)               | 11 (0.13)          | 9 (0.12)                | 2 (0.36)          |
| CeD (%)                 | 461 (1.38)               | 74 (0.90)          | 71 (0.92)               | 3 (0.54)          |

BMI, body mass index; CeD, celiac disease; COVID-19, coronavirus disease 2019.

---

**Table 4. The association between the risk factors and COVID-19 susceptibility and severe COVID-19**

| Phenotype                | COVID-19 susceptibility |              |     | Severe COVID-19 |              |     |
|--------------------------|-------------------------|--------------|-----|-----------------|--------------|-----|
|                          | OR                      | 95% CI       | \( P \) value | OR              | 95% CI       | \( P \) value |
| Age                      | 0.942                   | 0.939–0.945  | <0.001 | 1.134           | 1.119–1.148 | <0.001 |
| Age\(^a\)                | 0.941                   | 0.938–0.944  | <0.001 | 1.129           | 1.114–1.144 | <0.001 |
| Male                     | 1.038                   | 0.989–1.089  | 0.132  | 2.075           | 1.733–2.485 | <0.001 |
| Male\(^a\)               | NA                      | NA           | NA    | 1.793           | 1.484–2.165 | <0.001 |
| BMI                      | 1.022                   | 1.017–1.027  | <0.001 | 1.071           | 1.055–1.087 | <0.001 |
| BMI\(^a\)                | 1.026                   | 1.021–1.031  | <0.001 | 1.061           | 1.042–1.080 | <0.001 |
| Gluten-free diet         | 0.365                   | 0.197–0.677  | 0.001  | 3.089           | 0.666–14.334| 0.150  |
| Gluten-free diet\(^a\)   | 0.374                   | 0.199–0.701  | 0.002  | NA              | NA          | NA    |
| Diabetes                 | 0.909                   | 0.841–0.984  | 0.018  | 3.278           | 2.667–4.029 | <0.001 |
| Diabetes\(^a\)           | 0.978                   | 0.898–1.064  | 0.601  | 1.566           | 1.241–1.976 | <0.001 |
| CeD                      | 0.643                   | 0.503–0.823  | <0.001 | 0.584           | 0.183–1.859 | 0.362  |
| CeD\(^a\)                | 0.699                   | 0.542–0.901  | 0.006  | 0.873           | 0.256–2.975 | 0.431  |

BMI, body mass index; CeD, celiac disease; CI, confidence interval; COVID-19, coronavirus disease 2019; OR, odds ratio.

\(^a\)Multivariate regression analysis was used to identify the independent risk factors of COVID-19 susceptibility and severe COVID-19. “NA” represents that the phenotype was not adjusted in the multivariate regression analysis.
affect the immunity system may play a significant role as well. The human leukocyte antigen (HLA) gene cluster has been associated with CeD. As reported, the CeD risk allele of rs2187668-A near the HLA-DQA1 locus was also associated with immunoglobulin A deficiency (19) and decreased white blood cell count and neutrophil count (20), all of which were elevated in patients with severe COVID-19 (3,21). This hypothesis was further supported proven by the works of Luca and Fainareti et al. Luca et al. found that anti–SARS-CoV-2 IgA was lower in patients with CeD compared with healthy individuals (22). Fainareti et al. demonstrated that the high anti–SARS-CoV-2 IgA in patients increased the risk of severe COVID-19 (23). Meanwhile, a missense variant rs3184504-T in SH2B3 gene was associated with both higher risk of CeD and lower risk of obesity (24). Obesity and concomitant chronic inflammation were independent risk factors for severe COVID-19 (25). We believe that relatively lower BMI in patients with CeD (26) may contribute to the lower risk of severe COVID-19.

The impacts of rheumatoid arthritis, another common autoimmune disease, on severe COVID-19 have also been broadly concerning (27–29). Contrary to CeD, patients with rheumatoid arthritis are at a higher risk of severe COVID-19 (27–29). Interestingly, rs2187668-A was negatively associated with rheumatoid arthritis (30). Given the role of rs2187668-A in the immunity system, we hypothesized that the opposite risks of severe COVID-19 in patients with CeD and rheumatoid arthritis may be attributed to the different immune statuses of the patients. The mechanisms need to be investigated in future studies to clearly explain the opposite risks of severe COVID-19 in patients with CeD and rheumatoid arthritis.

Of course, our study could also be biased by a few intrinsic limitations, which may lead to confounded results. These may include unknown confounding factors, uncontrolled mask wearing, pleiotropic effects of selected IVs or shewed GWAS summary statistics if adjusted insufficiently, or included control subjects without a SARS-CoV-2 test result. Therefore, the attention should still be paid to the physical status of patients with CeD during the COVID-19 pandemic. The proposals from Luca et al. (31) may help clinicians in managing patients with CeD during the COVID-19 pandemic.

**Figure 1.** The association between the risk factors and COVID-19 susceptibility and severe COVID-19. (a) COVID-19 susceptibility and (b) severe COVID-19. Multivariate regression analysis was used to identify the independent risk factors of COVID-19 susceptibility and severe COVID-19. BMI, body mass index; CeD, celiac disease; COVID-19, coronavirus disease 2019; Gluten-free, gluten-free diet; OR, odds ratio.

**Figure 2.** The causal association between CeD and COVID-19 susceptibility and severe COVID-19. CeD, celiac disease; COVID-19, coronavirus disease 2019; OR, odds ratio.
In conclusion, our study observed a potentially protective effect of CeD on the susceptibility of COVID-19 and severe COVID-19 in cohorts of major European ancestry. Our study suggested that it may be unnecessary to take extra COVID-19 precaution in patients with CeD. The relationship underlying this inverse association between CeD and severe COVID-19 warrants further investigations.

CONFLICTS OF INTEREST
Guarantor of the article: Peng Chen, PhD.
Specific author contributions: J.L. and P.C. designed research. P.C. contributed to the acquisition of the UKB data. J.L., A.T., M.Z., and L.C. analyzed the data. J.W., P.C., and J.L. interpreted the results. J.L. wrote the first draft of the manuscript. All authors revised the manuscript and approved the submission.

Financial support: This work was supported by the “Changbai Mountain Scholar” Distinguished Professor Awarding Program of the Department of Education of Jilin Province, China.

Potential competing interests: None to report.

ACKNOWLEDGMENTS
The observational study was conducted in the UKB cohort under the application number 53536. We thank the COVID-19 Host Genetics Initiative for public COVID-19 GWAS summary statistics. We also thank Trynka G and Ricaño-Ponce and colleagues for providing the instrumental variables associated with CeD.

Study Highlights

WHAT IS KNOWN
✓ Observational studies did not draw a clear conclusion on the association between celiac disease (CeD) and COVID-19.
✓ A Mendelian randomization study could be used to detect the association without the effects of the risk factors that could confound observational studies.

WHAT IS NEW HERE
✓ A significant decreased susceptibility of COVID-19 and the risk of severe COVID-19 could be observed in patients with CeD.
✓ The CeD risk allele rs2187668-A near HLA-DQA1 is associated with decreased white blood cell count and neutrophil count. This pleiotropic effect may explain the decreased risk of severe COVID-19 in patients with CeD.

REFERENCES
1. WHO Coronavirus (COVID-19) dashboard. (https://covid19.who.int/—21-October-2021).
2. Rapp JL, Lieberman-Cribbin W, Tuminello S, et al. Male sex, severe obesity, older age, and chronic kidney disease are associated with COVID-19 severity and mortality in New York City. Chest 2021;159:112–5.
3. Zhang JJ, Cao YY, Tan G, et al. Clinical, radiological, and laboratory characteristics and risk factors for severity and mortality of 289 hospitalized COVID-19 patients. Allergy 2021;76:533–50.
4. Ebinger JE, Achamallah N, Ji H, et al. Pre-existing traits associated with Covid-19 illness severity. PLoS One 2020;15:e0236240.
5. Gao F, Zheng KI, Wang XB, et al. Obesity is a risk factor for greater COVID-19 severity. Diabetes Care 2020;43:e72–e74.
6. Dennis JM, Mateen BA, Sonabend R, et al. Type 2 diabetes and COVID-19-related mortality in the critical care setting: A national cohort study in England, March-July 2020. Diabetes Care 2021;44:50–7.
7. Barron E, Bakhi C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: A whole-population study. Lancet Diabetes Endocrinol 2020;8:813–22.
8. Singh P, Arora A, Strand TA, et al. Global prevalence of celiac disease: Systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018;16:823–36.e2.
9. Zingone F, D’Odorico A, Lorenzon G, et al. Risk of COVID-19 in celiac disease patients. Autoimmun Rev 2020;19:102639.
10. Lionetti E, Fabbrizi A, Catassi C. Prevalence of COVID-19 in Italian children with celiac disease: A cross-sectional study. Clin Gastroenterol Hepatol 2021;19:10175.
11. Zhen J, Stefanolo JP, Temprano MP, et al. The risk of contracting COVID-19 is not increased in patients with celiac disease. Clin Gastroenterol Hepatol 2021;19:391–3.
12. Lebwohl B, Larsson E, Soderling J, et al. Risk of severe COVID-19 in patients with celiac disease: A population-based cohort study. Clin Epidemiol 2021;13:121–30.
13. Uche-Anyia E, Husby S, Kaplan GG, et al. An international reporting registry of patients with celiac disease and COVID-19: Initial results from SECURE-CELIAC. Clin Gastroenterol Hepatol 2021;19:2435–7.e4.
14. Smith GD, Ebrahim S. ‘Mendelian randomisation’: Can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 2003;32:1–22.
15. Gaziano L, Giambartolomei C, Pereira AC, et al. Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. Nat Med 2021;27:668–76.
16. Trynka G, Hunt KA, Bokett NA, et al. Dense genotyping identifies and localizes multiple common and rare variant association signals in celiac disease. Nat Genet 2011;43:1193–201.
17. Ricaño-Ponce I, Gutierrez-Achury J, Costa AF, et al. Immunochip meta-analysis in European and Argentinian populations identifies two novel genetic loci associated with celiac disease. Eur J Hum Genet 2020;28:313–23.
18. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Hum Genet 2020;28:715–8.
19. Bronson PG, Chang D, Bhangale T, et al. Common variants at PVT1, ATG13-AMBRA1, AHII and CLEC16A are associated with selective IgA deficiency. Nat Genet 2016;48:1425–9.

Table 5. The causal association between celiac disease and COVID-19 susceptibility and severe COVID-19

| Stage          | Outcome              | Nsnp | OR   | 95% CI       | P value | Het-p | Ple-p |
|----------------|----------------------|------|------|--------------|---------|-------|-------|
| Discovery      | COVID-19 susceptibility | 23   | 0.963| 0.937–0.989 | 0.006   | 0.523 | 0.400 |
| Sensitivity analysis | COVID-19 susceptibility | 21   | 0.919| 0.844–0.999 | 0.049   | 0.522 | 0.676 |
| Severe COVID-19 | 0.975 | 0.943–1.008 | 0.126 | 0.574 | 0.577 |
| Severe COVID-19 | 0.903 | 0.820–0.994 | 0.037 | 0.321 | 0.396 |

CI, confidence interval; MR, Mendelian randomization; Nsnp, the number of instrumental variables used in MR; OR, odds ratio, calculated as the natural exponential of beta; P value, the P value of the 2-sample MR analysis; Het-p, the P value of heterogeneity; Ple-p, the P value of the pleiotropic effect; UKB, UK Biobank.

*The UKB samples were excluded in the sensitivity analysis.
20. Astle WJ, Elding H, Jiang T, et al. The allelic landscape of human blood cell trait variation and links to common complex disease. Cell 2016;167:1415–29.e19.
21. Hasan Ali O, Bomze D, Risch L, et al. Severe coronavirus disease 2019 (COVID-19) is associated with elevated serum immunoglobulin (Ig) A and antiphospholipid IgA antibodies. Clin Infect Dis 2021;73:e2869–e2874.
22. Elli L, Facciotti F, Lombardo V, et al. Anti-SARS-CoV-2 immunoglobulin profile in patients with celiac disease living in a high incidence area. Dig Liver Dis 2022;54:3–9.
23. Zervou FN, Louie P, Stachel A, et al. SARS-CoV-2 antibodies: IgA correlates with severity of disease in early COVID-19 infection. J Med Virol 2021;93:5409–15.
24. Turcot V, Lu Y, Highland HM, et al. Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity. Nat Genet 2018;50:26–41.
25. Freuer D, Linseisen J, Meisinger C. Impact of body composition on COVID-19 susceptibility and severity: A two-sample multivariable Mendelian randomization study. Metabolism 2021;118:154732.
26. Kabbani TA, Goldberg A, Kelly CP, et al. Body mass index and the risk of obesity in celiac disease treated with the gluten-free diet. Aliment Pharmacol Ther 2012;35:723–9.
27. Cordtz R, Lindhardsen J, Soussi BG, et al. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: A nationwide cohort study from Denmark. Rheumatology (Oxford) 2021;60:si59–si67.
28. England BR, Roul P, Yang Y, et al. Risk of COVID-19 in rheumatoid arthritis: A national veterans affairs matched cohort study in at-risk individuals. Arthritis Rheumatol 2021;73:2179–88.
29. Raiker R, DeYoung C, Pakhchanian H, et al. Outcomes of COVID-19 in patients with rheumatoid arthritis: A multicenter research network study in the United States. Semin Arthritis Rheum 2021;51:1057–66.
30. Okada Y, Wu D, Trynka G, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014;506:376–81.
31. Elli L, Barisani D, Vaira V, et al. How to manage celiac disease and gluten-free diet during the COVID-19 era: Proposals from a tertiary referral center in a high-incidence scenario. BMC Gastroenterol 2020;20:387.

Open Access This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.